ReviewDie Ophthalmologie2025
[Screening recommendations for glaucoma, age-related macular degeneration and diabetic eye diseases].
Review in Die Ophthalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe main causes of blindness, age-related macular degeneration (AMD), glaucoma and diabetic eye diseases (DED), are becoming increasingly more important in terms of health economics due to the demographic developments.
objectiveThe current screening recommendations for these diseases and the underlying evidence are presented. MATERIAL AND
methodsA detailed literature search was conducted and the recommendations of the relevant guidelines of the Association of the Scientific Medical Societies in Germany (AWMF) were summarized.
resultsThere are current screening recommendations for glaucoma and DED but there is still no consensus with respect to AMD. Screening for DED is financed by the statutory health insurance (SHI) and offered as part of routine care. Glaucoma screening is only covered by the SHI if certain risk factors are present and is not yet implemented across the board.
conclusionThere are established screening programs for DED that are financed by the SHI; however, there are AWMF recommendations for glaucoma but no SHI-financed screening programs and there are still no AWMF screening recommendations for AMD. Whether and to what extent screening programs are used by the respective target populations should be further investigated in studies.
Indexed as
Identifiers
40402186What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.